{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:02:21Z","timestamp":1793318541041,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s10549-025-07702-w","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:02:52Z","timestamp":1745280172000},"page":"79-86","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Impact of pembrolizumab on ovarian function in young triple-negative breast cancer patients treated with chemo-immunotherapy"],"prefix":"10.1007","volume":"212","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7262-845X","authenticated-orcid":false,"given":"Anne","family":"Perdrix","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Olympios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Rouvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Degremont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Fontaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baptiste","family":"Boitel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Vion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Leheurteur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7074-9282","authenticated-orcid":false,"given":"Florian","family":"Clatot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"key":"7702_CR1","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMoa2112651","volume":"386","author":"P Schmid","year":"2022","unstructured":"Schmid P, Cortes J, Dent R et al (2022) Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med 386:556\u2013567. https:\/\/doi.org\/10.1056\/NEJMoa2112651","journal-title":"N Engl J Med"},{"key":"7702_CR2","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","volume":"391","author":"P Schmid","year":"2024","unstructured":"Schmid P, Cortes J, Dent R et al (2024) Overall survival with pembrolizumab in early-stage triple-negative breast cancer. N Engl J Med 391:1981\u20131991. https:\/\/doi.org\/10.1056\/NEJMoa2409932","journal-title":"N Engl J Med"},{"key":"7702_CR3","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.annonc.2022.07.1941","volume":"33","author":"I Vaz-Luis","year":"2022","unstructured":"Vaz-Luis I, Masiero M, Cavaletti G et al (2022) ESMO expert consensus statements on cancer survivorship: promoting high-quality survivorship care and research in Europe. Ann Oncol 33:1119\u20131133. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.1941","journal-title":"Ann Oncol"},{"key":"7702_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/PPO.0000000000000500","volume":"27","author":"FM Howard","year":"2021","unstructured":"Howard FM, Olopade OI (2021) Epidemiology of triple-negative breast cancer: a review. Cancer J 27:8\u201316. https:\/\/doi.org\/10.1097\/PPO.0000000000000500","journal-title":"Cancer J"},{"key":"7702_CR5","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1002\/ijc.33933","volume":"150","author":"A Mailliez","year":"2022","unstructured":"Mailliez A, Pigny P, Bogart E et al (2022) Is ovarian recovery after chemotherapy in young patients with early breast cancer influenced by controlled ovarian hyperstimulation for fertility preservation or tumor characteristics? Results of a prospective study in 126 patients. Int J Cancer 150:1850\u20131860. https:\/\/doi.org\/10.1002\/ijc.33933","journal-title":"Int J Cancer"},{"key":"7702_CR6","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1093\/humupd\/dmac004","volume":"28","author":"RA Anderson","year":"2022","unstructured":"Anderson RA, Cameron D, Clatot F et al (2022) Anti-M\u00fcllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review. Hum Reprod Update 28:417\u2013434. https:\/\/doi.org\/10.1093\/humupd\/dmac004","journal-title":"Hum Reprod Update"},{"key":"7702_CR7","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.rbmo.2021.09.004","volume":"44","author":"PL Bussies","year":"2022","unstructured":"Bussies PL, Richards EG, Rotz SJ, Falcone T (2022) Targeted cancer treatment and fertility: effect of immunotherapy and small molecule inhibitors on female reproduction. Reprod Biomed Online 44:81\u201392. https:\/\/doi.org\/10.1016\/j.rbmo.2021.09.004","journal-title":"Reprod Biomed Online"},{"key":"7702_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114010","volume":"202","author":"H Helgadottir","year":"2024","unstructured":"Helgadottir H, Matikas A, Fernebro J et al (2024) Fertility and reproductive concerns related to the new generation of cancer drugs and the clinical implication for young individuals undergoing treatments for solid tumors. Eur J Cancer 202:114010. https:\/\/doi.org\/10.1016\/j.ejca.2024.114010","journal-title":"Eur J Cancer"},{"key":"7702_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s43018-022-00413-x","volume":"3","author":"AL Winship","year":"2022","unstructured":"Winship AL, Alesi LR, Sant S et al (2022) Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice. Nat Cancer 3:1\u201313. https:\/\/doi.org\/10.1038\/s43018-022-00413-x","journal-title":"Nat Cancer"},{"key":"7702_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100276","volume":"6","author":"M Garutti","year":"2021","unstructured":"Garutti M, Lambertini M, Puglisi F (2021) Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review. ESMO Open 6:100276. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100276","journal-title":"ESMO Open"},{"key":"7702_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102769","volume":"128","author":"G Gentile","year":"2024","unstructured":"Gentile G, Scagnoli S, Arecco L et al (2024) Assessing risks and knowledge gaps on the impact of systemic therapies in early breast cancer on female fertility: a systematic review of the literature. Cancer Treat Rev 128:102769. https:\/\/doi.org\/10.1016\/j.ctrv.2024.102769","journal-title":"Cancer Treat Rev"},{"key":"7702_CR12","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3389\/fonc.2019.00575","volume":"9","author":"M Lambertini","year":"2019","unstructured":"Lambertini M, Olympios N, Lequesne J et al (2019) Impact of taxanes, endocrine therapy, and deleterious germline BRCA mutations on anti-m\u00fcllerian hormone levels in early breast cancer patients treated with anthracycline- and cyclophosphamide-based chemotherapy. Front Oncol 9:575. https:\/\/doi.org\/10.3389\/fonc.2019.00575","journal-title":"Front Oncol"},{"key":"7702_CR13","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s10549-021-06508-w","volume":"192","author":"RA Anderson","year":"2022","unstructured":"Anderson RA, Kelsey TW, Perdrix A et al (2022) Diagnostic and predictive accuracy of anti-Mullerian hormone for ovarian function after chemotherapy in premenopausal women with early breast cancer. Breast Cancer Res Treat 192:273\u2013282. https:\/\/doi.org\/10.1007\/s10549-021-06508-w","journal-title":"Breast Cancer Res Treat"},{"key":"7702_CR14","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1093\/annonc\/mdy127","volume":"29","author":"F Poggio","year":"2018","unstructured":"Poggio F, Bruzzone M, Ceppi M et al (2018) Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann Oncol 29:1497\u20131508. https:\/\/doi.org\/10.1093\/annonc\/mdy127","journal-title":"Ann Oncol"},{"key":"7702_CR15","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ejca.2022.05.013","volume":"173","author":"N Rives","year":"2022","unstructured":"Rives N, Courbi\u00e8re B, Almont T et al (2022) What should be done in terms of fertility preservation for patients with cancer? The French 2021 guidelines. Eur J Cancer 173:146\u2013166. https:\/\/doi.org\/10.1016\/j.ejca.2022.05.013","journal-title":"Eur J Cancer"},{"key":"7702_CR16","doi-asserted-by":"publisher","first-page":"e415","DOI":"10.1016\/S1470-2045(23)00390-X","volume":"24","author":"W Cui","year":"2023","unstructured":"Cui W, Rocconi RP, Thota R et al (2023) Measuring ovarian toxicity in clinical trials: an American society of clinical oncology research statement. Lancet Oncol 24:e415\u2013e423. https:\/\/doi.org\/10.1016\/S1470-2045(23)00390-X","journal-title":"Lancet Oncol"},{"key":"7702_CR17","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1200\/JCO.22.01885","volume":"41","author":"AC Reynolds","year":"2023","unstructured":"Reynolds AC, McKenzie LJ (2023) Cancer treatment-related ovarian dysfunction in women of childbearing potential: management and fertility preservation options. J Clin Oncol 41:2281\u20132292. https:\/\/doi.org\/10.1200\/JCO.22.01885","journal-title":"J Clin Oncol"},{"key":"7702_CR18","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1093\/humupd\/dmt062","volume":"20","author":"D Dewailly","year":"2014","unstructured":"Dewailly D, Andersen CY, Balen A et al (2014) The physiology and clinical utility of anti-Mullerian hormone in women. Hum Reprod Update 20:370\u2013385. https:\/\/doi.org\/10.1093\/humupd\/dmt062","journal-title":"Hum Reprod Update"},{"key":"7702_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/cob.12559","volume":"12","author":"J Kloos","year":"2022","unstructured":"Kloos J, Coyne K, Weinerman R (2022) The relationship between anti-M\u00fcllerian hormone, body mass index and weight loss: a review of the literature. Clin Obes 12:e12559. https:\/\/doi.org\/10.1111\/cob.12559","journal-title":"Clin Obes"},{"key":"7702_CR20","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1210\/jc.2012-3995","volume":"98","author":"M D\u00f3lleman","year":"2013","unstructured":"D\u00f3lleman M, Verschuren WMM, Eijkemans MJC et al (2013) Reproductive and lifestyle determinants of anti-M\u00fcllerian hormone in a large population-based study. J Clin Endocrinol Metab 98:2106\u20132115. https:\/\/doi.org\/10.1210\/jc.2012-3995","journal-title":"J Clin Endocrinol Metab"},{"key":"7702_CR21","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1200\/JCO.20.02880","volume":"39","author":"V Turan","year":"2021","unstructured":"Turan V, Lambertini M, Lee D-Y et al (2021) Association of germline BRCA pathogenic variants with diminished ovarian reserve: a meta-analysis of individual patient-level data. JCO 39:2016\u20132024. https:\/\/doi.org\/10.1200\/JCO.20.02880","journal-title":"JCO"},{"key":"7702_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2024.103891","volume":"49","author":"C Decanter","year":"2024","unstructured":"Decanter C, Elefant E, Poirot C, Courbiere B (2024) What reproductive follow-up for adolescent and young women after cancer? A review. Reprod Biomed Online 49:103891. https:\/\/doi.org\/10.1016\/j.rbmo.2024.103891","journal-title":"Reprod Biomed Online"},{"key":"7702_CR23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.6004\/jnccn.2022.7065","volume":"21","author":"M Lambertini","year":"2023","unstructured":"Lambertini M, Ceppi M, Anderson RA et al (2023) Impact of Anti-HER2 therapy alone and with weekly paclitaxel on the ovarian reserve of young women with HER2-positive breast cancer. J Natl Compr Cancer Netw 21:33-41.e16. https:\/\/doi.org\/10.6004\/jnccn.2022.7065","journal-title":"J Natl Compr Cancer Netw"},{"key":"7702_CR24","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1038\/s41598-022-05357-x","volume":"12","author":"E Ntemou","year":"2022","unstructured":"Ntemou E, Vidal PD, Alexandri C et al (2022) Ovarian toxicity of carboplatin and paclitaxel in mouse carriers of mutation in BRIP1 tumor suppressor gene. Sci Rep 12:1658. https:\/\/doi.org\/10.1038\/s41598-022-05357-x","journal-title":"Sci Rep"},{"key":"7702_CR25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.43910","volume":"6","author":"R Kabirian","year":"2023","unstructured":"Kabirian R, Franzoi MA, Havas J et al (2023) Chemotherapy-related amenorrhea and quality of life among premenopausal women with breast cancer. JAMA Netw Open 6:e2343910. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.43910","journal-title":"JAMA Netw Open"},{"key":"7702_CR26","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1210\/clinem\/dgac039","volume":"107","author":"MI Cedars","year":"2022","unstructured":"Cedars MI (2022) Evaluation of female fertility-AMH and ovarian reserve testing. J Clin Endocrinol Metab 107:1510\u20131519. https:\/\/doi.org\/10.1210\/clinem\/dgac039","journal-title":"J Clin Endocrinol Metab"},{"key":"7702_CR27","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1093\/humupd\/dmac045","volume":"29","author":"SM Nelson","year":"2023","unstructured":"Nelson SM, Davis SR, Kalantaridou S et al (2023) Anti-M\u00fcllerian hormone for the diagnosis and prediction of menopause: a systematic review. Hum Reprod Update 29:327\u2013346. https:\/\/doi.org\/10.1093\/humupd\/dmac045","journal-title":"Hum Reprod Update"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07702-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-025-07702-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07702-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T03:24:09Z","timestamp":1747538649000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-025-07702-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["7702"],"URL":"https:\/\/doi.org\/10.1007\/s10549-025-07702-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5947113\/v1","asserted-by":"object"}]},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,22]]},"assertion":[{"value":"2 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"FC has received honoraria and\/or travel grants from Astra Zeneca, Daiichi, Gilead, MSD, Merck Serono, Nutricia, Novartis outside the submitted work. ML has received payment of congress fees from Daiichi, Lilly, MSD, Pfizer, GSK, Novartis, Mundi pharma, EISAI; and has undertaken consultancy for MSD, Astra-Zeneca, Pierre Fabre, GSK, Lilly and Seagen outside the submitted work. NO has received payment of congress fees from Pfizer, Gillead and Lilly; and has undertaken consultancy for Gilead and Astra Zeneca outside the submitted work. The other authors report no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The present study follows the French reference methodology MR-004 and was approved by the Institutional Scientific and Ethics Committees of Henri Becquerel Center (registering order N\u00b02406B).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients signed a consent form allowing the conservation and use of their biological samples. No patient objected to the use of the anonymous data generated for research purposes, according to MR-004 methodology.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"This manuscript does not contain any individual personal data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}